Core Viewpoint - The company is actively developing brain-computer interface technology, leveraging its integrated circuit design advantages to focus on providing foundational hardware components for signal processing [1] Group 1: Technology Development - The company utilizes high-precision ADC (Analog-to-Digital Converter) for neural signal acquisition and employs low-power FPGA (Field-Programmable Gate Array) and MCU (Microcontroller) for signal post-processing [1] - The technology development covers both invasive and non-invasive brain-computer interface signal chain requirements, including the research and application of 24-bit sigma-delta high-precision ADC and low-power MCU chips [1] Group 2: Collaborations and Projects - The company has completed part of the acceptance for key projects in collaboration with universities such as Shanghai Jiao Tong University and Tianjin University [1] - The company will continue to monitor technological trends and market demands while steadily advancing its product layout based on its R&D capabilities [1] Group 3: Information Disclosure - The company commits to adhering to information disclosure regulations and will announce specific progress in a timely manner, relying on official disclosures for accurate information [1]

Core Viewpoint - Chengdu Huami has made significant advancements in the brain-computer interface technology sector, focusing on providing foundational hardware components for signal processing [1] Group 1: Company Developments - The company leverages its integrated circuit design advantages to develop solutions in the brain-computer interface field [1] - Chengdu Huami utilizes high-precision ADCs (Analog-to-Digital Converters) for neural signal acquisition and employs low-power FPGAs (Field-Programmable Gate Arrays) and MCUs (Microcontrollers) for signal post-processing [1] - The company collaborates with prestigious universities such as Shanghai Jiao Tong University and Tianjin University on key projects, some of which have already completed acceptance testing [1] Group 2: Technology and Products - The technology developed by the company covers the full signal chain requirements for both invasive and non-invasive brain-computer interfaces [1] - The product offerings include 24-bit sigma-delta structure high-precision ADCs and low-power MCUs, which are crucial for the development and application of brain-computer interface technologies [1]

Group 1 - The brain-computer interface (BCI) sector has seen significant advancements since 2025, with related stocks experiencing substantial increases, such as Saily Medical up 165.37% and Innovative Medical up 92.46% as of July 3 [1] - The A-share BCI sector has an overall increase of 49.1% this year, indicating a strong market sentiment towards this industry [1] - Policy support has been a driving force, with cities like Beijing and Shanghai launching five-year action plans for BCI development, aiming to cultivate innovative enterprises and achieve clinical application of BCI products by 2030 [1][2] Group 2 - The establishment of China's first BCI industrial cluster in Shanghai marks a significant step in the domestic BCI landscape, with the new facility expected to be operational within the year [2] - The stock market has reacted positively, with multiple BCI-related stocks experiencing consecutive gains, such as Saily Medical and Jihua Group achieving three consecutive trading limits [2] - The BCI theme index in A-shares has risen by 4.96% over the past month, reflecting ongoing investor interest [2] Group 3 - Companies are increasingly engaging with investors regarding BCI developments, with Chengyitong announcing a dual-track strategy in invasive and non-invasive BCI technologies [3] - Chengyitong plans to release three prototypes of neuro-rehabilitation devices integrating BCI technology by July 2024 [3] - Other companies, such as Chengdu Huamei and Pulite, are also exploring BCI applications, focusing on signal processing hardware and high-performance materials, respectively [3]